ZAY0 Stock Chart & Stats
€0.37
-€0.01(-2.46%)
At close: 4:00 PM EDT
€0.37
-€0.01(-2.46%)
Day’s Range― - ―
52-Week Range€0.32 - €0.90
Previous CloseN/A
Volume0.00
Average Volume (3M)173.00
Market Cap
€57.77M
Enterprise Value€60.34M
Total Cash (Recent Filing)€16.60M
Total Debt (Recent Filing)€1.93M
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume0
30 Day Avg. Volume173
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.69Price Target Upside356.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageModest leverage and meaningful equity provide Zentek with a financial cushion while it develops and commercializes its technologies. Lower refinancing and solvency risk preserves strategic flexibility, although continued losses could gradually reduce that cushion if operating performance does not improve.
Government CommercializationThe federal standing offer provides evidence that Zentek has moved beyond research toward institutional commercialization of ZenGUARD filters. While the stated maximum value is modest, government procurement validation can support customer credibility and create a platform for broader adoption over the next several quarters.
Expanding IP PipelineA new provisional patent expands Zentek’s protected technology portfolio into EMI shielding coatings, an additional application for its advanced-materials platform. Continued intellectual property generation can support licensing, partnerships, and differentiated product development if the technology progresses toward commercial deployment.
Bears Say
Weak Revenue TractionExtremely small and declining revenue indicates that Zentek has not yet established durable commercial traction across its materials technologies. This limits operating scale, reduces internally generated funding for development, and leaves the company dependent on future commercialization progress to improve its financial profile.
Persistent LossesRepeated net losses and negative operating results show that the current business model has not reached sustainable profitability. A brief period of positive annual gross profit did not establish stable margins, so Zentek’s ability to convert product development and intellectual property into durable earnings remains unproven.
Ongoing Cash BurnConsistently negative operating and free cash flow means Zentek is not yet self-funding its operations or development activities. Ongoing cash burn can consume the balance-sheet cushion over time and may constrain investment capacity unless revenue growth, margins, or commercialization proceeds improve materially.
Zentek News
ZAY0 FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was €0.32 and its highest was €0.90 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is €57.77M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Nov 16, 2026 which is in 41 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Aug 14, 2026. The company reported -€0.011 earnings per share for the quarter.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Undervalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 126,619,530 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -€0.011 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in DE:ZAY0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.69 (356.07% Upside)
€1.69 (356.07% Upside)
Insider Transactions
Bought Shares
Worth €20.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
ZAY0 Stock 12 Month Forecast
Average Price Target
€1.69
▲(356.07% Upside)
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―